The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Results of the phase III CLL1 trial – risk adapted therapy of fludarabine or watch and wait in patients with early stage CLL

Sep 8, 2017

In a Letterto the Editor of Leukemia, Manuela A. Hoechstetterfrom Klinikum Schwabing, Munich, Germany, et al.reported findings from the CLL1 trial conducted by the German CLL study group( NCT00262782).

The CLL1 trial aimed to investigate risk-adapted therapy in patients with early stage (0–II) Chronic Lymphocytic Leukemia (CLL). The trial’s protocol was designed in 1997 and identified High-Risk (HR) patients who may progress and receive subsequent treatment ≤2 years after diagnosis either by Lymphocyte Doubling Time (LDT) of less than 12 months or Bone Marrow Infiltration Pattern (BMIP). HR patients were randomly assigned, at a ratio of 1:1, to either early fludarabine (HR-F: 25mg/m2 IV, days 1–5, q28 x 6 cycles) or watch and wait (HR-W&W).

CLL1 was carried out in 123 centers in Germany and Austria and the primary endpoint was PFS. Secondary measures included OS and Time-To-First-Treatment (TTFT).

Key Highlights:

Patients and treatment:

  • In total, 189 HR pts included: HR-F = 93 pts; HR-W&W = 96 pts
  • Completed ≥1 course = 70 pts; one patient discontinued after 2 days due to intolerance
  • Not treated = 22 (drop-out rate = 24.7%); these were followed with W&W without further information
  • Total course administered = 388 (median = 6)
  • Courses administered at planned doses = 373 (96%); dose reduction by >50% = 9 courses (2.3%); dose reduction by >25% = 6 courses (2.1%)
  • Full 6 courses administered to 57/70 HR-F pts (80.3%)

Efficacy:

  • ORR = 91.4%; CR = 27 pts (38.6%); PR = 37 pts (52.9%); SD = 5 pts (7.1%); PD = 1 patient (1.4%)
  • Median follow-up = 8.5 years (range, 0–13.9)
  • In all pts:
    • Median PFS = 59.4 months (95% CI, 47.2–71.6)
    • Median TTFT = 110.2 months (95% CI, 95.9–124.6)
    • Median OS = not reached (74.7% alive at 10 years)
  • HR versusLow-Risk (LR) pts:
    • Median PFS = 2.1 months (95% CI, 14.6–28.1) versus1 months (95% CI, 61.4–74.8); P< 0.001
    • Median TTFT = 53.8 months (95% CI, 42.3–65.4) versusnot reached; P< 0.001
    • Median OS = 130.2 months (95% CI, 116.1–144.3) versusnot reached; P< 0.001
  • HR-F versusHR-W&W pts:
    • Median PFS = 30.1 months (95% CI, 21.7–38.5) versus9 months (95% CI, 8.9–16.9); P< 0.001
    • Median TTFT = 74.2 months (95% CI, 54.7–93.8) versus1 months (95% CI, 29.1–53.1); P= 0.04
    • Median OS = 126.8 months (95% CI, 110.9–142.7) versusnot reached; P= 0.75 (not significant)

Toxicity:

  • AEs observed in 248 courses (63.9%); hematologic toxicities were most common
  • Most frequent non-hematological AEs = infections, allergic reactions, and liver enzyme elevation
  • No treatment related deaths reported
  • Overall, 148 deaths (20.8%) occurred; HR-F = 38 (40.9%); HR-W&W = 35 (36.5%); LR = 75 (14.4%)
  • Most pts died from CLL (n=59, 39.9%)
  • Death due to Secondary Primary Malignancy (SPM) reported in 23 pts (15.5%); the most common malignancies were lung and gastrointestinal cancers
  • Richter’s Transformation, including one Hodgkin Lymphoma, resulted in the death of 5 pts (one HR patient, 4 LR pts)
  • Other reasons caused the deaths of 36 pts (24.3%) primarily infections (44.4%) and coronary heart disease (19.4%)

The authors stated that their findings support watch and wait as the current standard of care for early stage CLL. The group, based on their results, also caution not to treat too early. Lastly, they emphasize that novel agents require “rigorous testing in randomized trials before being approved or generally used in early stage CLL.”

Abstract:

N/A

  1. Hoechstetter M.A. et al.Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group. Leukemia.2017 Aug 14. DOI: 10.1038/leu.2017.246.[Epub ahead of print].